Digital lifestyle management application (levidex) for empowerment and health behaviour change in early multiple sclerosis - Results of the randomised controlled POWER@MS1 trial.

ABSTRACT:

Background

This randomised controlled trial investigated the effect of a personalised digital lifestyle management application ('levidex') on inflammatory disease activity in newly diagnosed people with MS (pwMS), compared to a non-personalised application ('dexilev') that covered similar lifestyle-related content.

Methods

Participants (N = 234) were recruited from July 2019 to April 2022 in 20 study centres in Germany and randomised to levidex (intervention group (IG), n = 115) or 'dexilev' (control group (CG), n = 119). Follow-up data was collected over 1-2 years. The combined primary endpoint (new T2 lesion and/or relapse) was analysed using Cox proportional hazards regression. Key secondary endpoints included self-reported quality of life and health

SUBMITTER: Krause N 

PROVIDER: S-EPMC12432284 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature